CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination

• Published in: NAR cancer Vol. 5; no. 3; p. zcad039
• Main Authors: Brown, Victoria E, Moore, Sydney L, Chen, Maxine, House, Nealia, Ramsden, Philip, Wu, Hsin-Jung, Ribich, Scott, Grassian, Alexandra R, Choi, Yoon Jong
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.09.2023
• Subjects: DNA Damage Sensing and Repair; Editor's Choice
• ISSN: 2632-8674; 2632-8674
• DOI: 10.1093/narcan/zcad039

Abstract CCNE1 amplification is a common alteration in high-grade serous ovarian cancer and occurs in 15–20% of these tumors. These amplifications are mutually exclusive with homologous recombination deficiency, and, as they have intact homologous recombination, are intrinsically resistant to poly (ADP-ribose) polymerase inhibitors or chemotherapy agents. Understanding the molecular mechanisms that lead to this mutual exclusivity may reveal therapeutic vulnerabilities that could be leveraged in the clinic in this still underserved patient population. Here, we demonstrate that CCNE1-amplified high-grade serous ovarian cancer cells rely on homologous recombination to repair collapsed replication forks. Cyclin-dependent kinase 2, the canonical partner of cyclin E1, uniquely regulates homologous recombination in this genetic context, and as such cyclin-dependent kinase 2 inhibition synergizes with DNA damaging agents in vitro and in vivo. We demonstrate that combining a selective cyclin-dependent kinase 2 inhibitor with a DNA damaging agent could be a powerful tool in the clinic for high-grade serous ovarian cancer. Graphical Abstract Graphical Abstract